diabetes

Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Fierce Pharma
FDA
Merck
biosimilars
Lusduna Nexvue
Lantus
diabetes
Sanofi
Hatch Waxman Act
Flag link:
Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment
Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment
Drug Delivery Business News
Abbott Labs
devices
diabetes
Miles White
Bigfoot Biomedical
Flag link:
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
Seeking Alpha
MannKind
Afrezza
drug ads
diabetes
investors
inhaled insulin
Flag link:
Diabetes drugmakers partner with mobile startups to boost patient engagement
Diabetes drugmakers partner with mobile startups to boost patient engagement
Medical Marketing and Media
diabetes
mobile apps
patients
Novo Nordisk
Glooko
Roche
mySugr
Flag link:
Lawsuit stalls approval of Merck’s insulin injection
Lawsuit stalls approval of Merck’s insulin injection
Drug Delivery Business News
Merck
insulin
diabetes
Lusduna Nexvue
Flag link:
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
JNJ
Invokana
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
King cancer: The top 10 therapeutic areas in biopharma R&D
King cancer: The top 10 therapeutic areas in biopharma R&D
Endpoints
R&D
cancer
neurology
infection
immunology
cardiovascular disease
diabetes
Flag link:
Feinstein Institute receives $1m grant to develop bioelectronic pancreas
Feinstein Institute receives $1m grant to develop bioelectronic pancreas
Mass Device
diabetes
grants
devices
Feinstein Institute
bioelectronic pancreas
Flag link:
Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech
Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech
Mass Device
Abbott Labs
Bigfoot Biomedical
devices
insulin delivery
diabetes
Flag link:
Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’
Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’
Drug Delivery Business News
Capillary Biomedical
diabetes
insulin infusion device
devices
Flag link:
Novo Nordisk Warns of Possible Cracks in Insulin Devices
Novo Nordisk Warns of Possible Cracks in Insulin Devices
RAPS.org
Novo Nordisk
insulin
diabetes
devices
NovoPen Echo
Flag link:
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Novo Nordisk touts late-stage trial data for Tresiba insulin injection
Drug Delivery Business News
Novo Nordisk
Tresiba
insulin
clinical trials
diabetes
Flag link:
MannKind - Afrezza Scripts Come Back Down After ADA Conference Bump
MannKind - Afrezza Scripts Come Back Down After ADA Conference Bump
Seeking Alpha
Afrezza
MannKind
diabetes
inhaled insulin
Flag link:
Roche buys mySugr diabetes app
Roche buys mySugr diabetes app
Drug Delivery Business News
Roche
mySugr
mobile apps
diabetes
devices
Flag link:
MannKind: Afrezza Sales See Best Result In More Than A Year
MannKind: Afrezza Sales See Best Result In More Than A Year
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
Medtronic inks diabetes deal with Aetna
Medtronic inks diabetes deal with Aetna
Mass Device
Medtronic
Aetna
diabetes
devices
insulin pumps
MiniMed 670G
Flag link:
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
Medical Marketing and Media
diabetes
blood sugar
competition
Novo Nordisk
Victoza
Eli Lilly
Jardiance
Invokana
JNJ
Flag link:
FDA panel supports cardiovascular indication for Novo’s diabetes drug Victoza
FDA panel supports cardiovascular indication for Novo’s diabetes drug Victoza
Fierce Pharma
FDA
advisory panels
Novo Nordisk
diabetes
Victoza
Flag link:
Novo Nordisk files to add Lantus-matching CV data to Tresiba's European label
Novo Nordisk files to add Lantus-matching CV data to Tresiba's European label
Fierce Pharma
Novo Nordisk
Lantus
Tresiba
diabetes
Europe
EMA
insulin
Flag link:
MannKind’s Afrezza needs a big turn. Can reality TV and a new commercial get it done?
MannKind’s Afrezza needs a big turn. Can reality TV and a new commercial get it done?
Fierce Pharma
MannKind
Afrezza
diabetes
television ads
drug marketing
Flag link: